Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) was the recipient of a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 38,900 shares, a decline of 23.6% from the July 15th total of 50,900 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 42,900 shares, the short-interest ratio is currently 0.9 days.
In other news, Director Leonard Sank purchased 20,000 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was purchased at an average price of $3.47 per share, for a total transaction of $69,400.00. Following the completion of the acquisition, the director now owns 315,482 shares of the company’s stock, valued at $1,094,722.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 25,817 shares of company stock valued at $91,009 in the last quarter. 20.50% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of ORMP. Renaissance Technologies LLC lifted its holdings in Oramed Pharmaceuticals by 50.5% during the second quarter. Renaissance Technologies LLC now owns 158,098 shares of the biotechnology company’s stock worth $568,000 after buying an additional 53,043 shares during the period. Jane Street Group LLC acquired a new position in shares of Oramed Pharmaceuticals during the second quarter worth $155,000. Finally, BlackRock Inc. increased its position in shares of Oramed Pharmaceuticals by 137.2% during the fourth quarter. BlackRock Inc. now owns 69,343 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 40,114 shares in the last quarter. Institutional investors own 6.47% of the company’s stock.
Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Wednesday, July 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.71 million. Oramed Pharmaceuticals had a negative return on equity of 56.15% and a negative net margin of 568.43%. As a group, equities research analysts predict that Oramed Pharmaceuticals will post -0.98 EPS for the current fiscal year.
ORMP has been the subject of a number of research reports. ValuEngine upgraded Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating on shares of Oramed Pharmaceuticals in a report on Wednesday, June 19th.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Further Reading: Why do company’s buyback their stock?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.